Aurora Cannabis reports Q2-2026 revenue growth with stronger international sales but posts net loss and negative free cash flow. Learn why ACB stock is a hold.

Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.

Aurora Cannabis Inc. is rated a Buy with 40% upside in current levels and expects solid growth in medical cannabis sales.

Analysts have upgraded Aurora Cannabis (ACB) and Tesla (TSLA), driven by positive growth expectations and strategic ...

Looking ahead, Aurora expects its third-quarter 2026 consolidated revenue to increase year over year, led by 8% to 12% growth in global medical cannabis sales. Management also projects continued ...

Wednesday, November 5, 2025Like an oasis in the desert, this morning’s Automatic Data Processing ADP private-sector payroll report for October is out ahead of today’s opening bell. If these were ...

Doughnut chain Krispy Kreme (NASDAQ:DNUT) will be reporting earnings this Thursday before market hours. Here’s what to expect ...

Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.04 per share a year ago. These ...

Our merger arbitrage strategy returned +4.0% before expenses (+3.0% net) in the third quarter and +13.8% before expenses (+10.4% net) for the ...

Expands YoY Global Medical Cannabis Net Revenue 1 by 15% to Record $70.5 million Increases International Medical Cannabis Net ...